COMTD1: A Drug Target / Disease Biomarker (G118881)

Target Name: COMTD1

NCBI ID: G118881

COMTD1

Other Name(s): Catechol-O-methyltransferase domain containing 1 | catechol-O-methyltransferase domain containing 1 | CMTD1_HUMAN | Catechol O-methyltransferase domain-containing protein 1 | FLJ23841 | Catechol O-methyltransferase domain-containing protein 1 (COMTD1)

COMTD1: A Drug Target / Disease Biomarker

COMTD1, also known as GABA-ZY1, is a protein that is expressed in various tissues throughout the body, including the brain, nervous system, and heart. It is a key regulator of GABA, a neurotransmitter that plays a crucial role in brain function and is involved in a wide range of physiological processes.

Research has shown that COMTD1 is involved in a number of important cellular processes in the brain, including modulating the strength of neural circuits, regulating neurotransmitter release, and contributing to the development and maintenance of neural plasticity. It is also involved in the regulation of pain perception and resilience, as well as in the modulation of sleep-wake cycles.

COMTD1 is a potential drug target for a variety of neurological and psychiatric disorders, including epilepsy, anxiety, and depression. It is also a potential biomarker for some of these disorders, as its levels can be affected by a variety of factors, including genetic and environmental factors.

One of the key challenges in studying COMTD1 is its complex cellular localization and regulation. While it is well known that COMTD1 is involved in various signaling pathways in the brain, its precise mechanism of action and the cells in which it is expressed are not yet fully understood.

One potential mechanism by which COMTD1 may contribute to neural circuits is through its role in modulating the strength of synaptic connections between neurons. Synaptic connections, also known as synapses, are the points of contact between neurons and are involved in the transmission of electrical signals in the brain.

Research has shown that COMTD1 is involved in the regulation of synaptic strength, including the strengthening and weakening of connections between neurons. This may be important for the development and maintenance of neural circuits, as well as for the regulation of cognitive function.

Another potential mechanism by which COMTD1 may contribute to neural circuits is through its role in modulating neurotransmitter release. Neurons release neurotransmitters, such as dopamine and GABA, in response to various stimuli and are involved in the regulation of neural circuits.

COMTD1 is involved in the regulation of neurotransmitter release through its effects on the release of various neurotransmitter vesicles. This may be important for the regulation of neural circuits, as neurotransmitters are involved in the transmission of signals between neurons.

In addition to its role in modulating neural circuits, COMTD1 is also involved in the regulation of pain perception and resilience, as well as in the modulation of sleep-wake cycles. These functions are important for maintaining the homeostasis of the body and are involved in the regulation of many physiological processes, including the regulation of body temperature, heart rate, and blood pressure.

COMTD1 is also involved in the regulation of resilience, which is the ability of the body to recover from or adapt to various stimuli. This may be important for the regulation of stress responses and the regulation of overall health and well-being.

In addition to its role in modulating neural circuits and contributing to the regulation of various physiological processes, COMTD1 is also involved in the regulation of pain perception and resilience. These functions are important for maintaining the homeostasis of the body and are involved in the regulation of many physiological processes.

COMTD1 is a protein that is expressed in various tissues throughout the body and is involved in a wide range of cellular processes, including the regulation of neural circuits, neurotransmitter release, and the regulation of pain perception and resilience. It is a potential drug target for a variety of neurological and psychiatric disorders, including epilepsy, anxiety, and depression, as well as a potential biomarker for some of these disorders. Further research is needed to fully understand the precise mechanism of action and

Protein Name: Catechol-O-methyltransferase Domain Containing 1

Functions: Putative O-methyltransferase

The "COMTD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COMTD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets